GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » Short-Term Debt & Capital Lease Obligation

Vicapsys Life Sciences (Vicapsys Life Sciences) Short-Term Debt & Capital Lease Obligation : $0.31 Mil (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Vicapsys Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.31 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Vicapsys Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.


Vicapsys Life Sciences Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Vicapsys Life Sciences's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicapsys Life Sciences Short-Term Debt & Capital Lease Obligation Chart

Vicapsys Life Sciences Annual Data
Trend Dec08 Dec09 Dec19 Dec20 Dec21 Dec22
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial 1.43 - - - -

Vicapsys Life Sciences Quarterly Data
Jun10 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.26 0.31

Vicapsys Life Sciences Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Vicapsys Life Sciences Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vicapsys Life Sciences's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description

Industry
Traded in Other Exchanges
N/A
Address
7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
Executives
Moore Bobby M Jr 10 percent owner 4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen 10 percent owner 9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski director 1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping 10 percent owner 2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees director C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser director 641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier director 1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon director, 10 percent owner 8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines

From GuruFocus